Download MendeleyDesign and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers.
Nishiguchi, G.A., Rico, A., Tanner, H., Aversa, R.J., Taft, B.R., Subramanian, S., Setti, L., Burger, M.T., Wan, L., Tamez, V., Smith, A., Lou, Y., Barsanti, P.A., Appleton, B.A., Mamo, M., Tandeske, L., Dix, I., Tellew, J.E., Huang, S., Mathews Griner, L.A., Cooke, V.G., Van Abbema, A., Merritt, H., Ma, S., Gampa, K., Feng, F., Yuan, J., Wang, Y., Haling, J.R., Vaziri, S., Hekmat-Nejad, M., Jansen, J.M., Polyakov, V., Zang, R., Sethuraman, V., Amiri, P., Singh, M., Lees, E., Shao, W., Stuart, D.D., Dillon, M.P., Ramurthy, S.(2017) J Med Chem 60: 4869-4881
- PubMed: 28557458
- DOI: 10.1021/acs.jmedchem.6b01862
- Primary Citation of Related Structures:
5VAL, 5VAM - PubMed Abstract:
RAS oncogenes have been implicated in >30% of human cancers, all representing high unmet medical need. The exquisite dependency on CRAF kinase in KRAS mutant tumors has been established in genetically engineered mouse models and human tumor cells. To date, many small molecule approaches are under investigation to target CRAF, yet kinase-selective and cellular potent inhibitors remain challenging to identify ...
